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Abstract
This editorial marks the launch of a special collection of articles highlighting ‘Five years of Trials’ (http://www.
trialsjournal.com/series/5years). The journal’s achievements on its objectives since 2006 are described and some of
the challenges still ahead are outlined - in particular further innovating in the reporting of trials and the
publication of negative results. The other articles in this series are examples of where Trials has demonstrated
progress on its objectives. These include the publication of raw data, extended versions of previously published
trial-related articles, descriptions of ‘lessons learned’, negative results, and educational articles regarding ethics and
reporting bias.
Introduction
We launched Trials to create a space for all types of
article related to randomised trials taking advantage of
the unlimited space provided by a web-based publication
[1]. Trials is a forum for discussing both specific rando-
mised trials as well as general issues applying to trials.
Over its five years of publication, Trials has become
recognised for its ambition to publish all trial results
regardless of their outcome [2], study protocols [3], and
critiques of trials published elsewhere [4]. Trials has
also encouraged innovation in trial reporting [5,6] and
stimulated debate in the medical research community
[7]. In this editorial, which marks the launch of a special
retrospective collection of articles highlighting ‘Five
years of Trials’ (http://www.trialsjournal.com/series/
5years), we discuss the journal’s achievements to date,
and outline some of the challenges still ahead.
The other eight articles featured in this series are
examples - although there are others - of where Trials
has demonstrated progress on its objectives since the
launch of the journal. These articles cover the publica-
tion of raw data; publication of extended versions of
articles previously published summarily elsewhere;
reflective, lessons learned, articles; negative results of
trials; and content of educational value on important
issues in trial conduct and reporting, such as ethics and
reporting bias, which might not have found suitable
publication venues before the existence of Trials.
Achievements
Protocol publication
“Trials will ... encourage the publication of protocols” [1]
Recent years have seen a move to greater transparency
in reporting research and especially randomised trials,
most obviously in the widespread requirement for trial
registration [8]. Also, five years ago evidence had begun
to accumulate of wide-scale discrepancies between trial
publications and what had been stated in the original
trial protocol [9]. Publication of trial protocols was
rarely possible in paper-based journals [10].
Increasing protocol publication is undoubtedly one of
Trials’ greatest successes. When the journal re-launched
as Trials in 2006 we published 21 study protocols in the
first year; in the first three quarters of 2011 we have
already published more than 100. This growth is a sig-
nificant achievement but has not been without its chal-
lenges. Publication of protocols has brought the
challenge of developing guidance for their peer review.
The peer-review process, and indeed whether this is
routinely required for protocols, has been an ongoing
discussion, and the process has been refined and
updated since we launched the journal. We have aimed
to promote transparency in trial reporting, by being
inclusive of submitted protocols - many of which have
undergone peer review during grant and ethical approval
applications - but have also aimed to publish responsi-
bly. Trials has rejected less than 20% of study protocols
submitted to the journal, the majority of these because
they fall outside of the journal’s scope - for example if
they describe non-randomised studies. However,
approximately 5% of study protocols have been rejected
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mentally - methodologically - flawed. Given the substan-
tial experience of the journal in protocol peer review
and publication, and the availability of peer reviews and
editors’ notes openly, as pre-publication history, we
intend to conduct a more detailed analysis of our
experience with protocol peer-review.
We eagerly anticipate the finalisation of the SPIRIT
(Standardised Protocol Items: Recommendations for
Interventional Trials) checklist [11] as an opportunity to
enhance our policies further. Meanwhile, four specific
points for peer reviewers of study protocols to consider
were added to our peer reviewer guidelines in August
2011 (see Appendix 1 and [12]). These take into account
the limited changes that can pragmatically be made to a
submitted study protocol without needing further ethical
approval while a trial is still ongoing.
Publication of raw data
“We will [also] encourage authors to make available all
(or some of) the raw data from the trials.” [1]
Trials has always encouraged authors to use the
opportunities afforded by electronic publishing to
include all or some of the raw data supporting the
results reported in their articles (additional data files are
considered integral to the associated articles, as opposed
to “supplementary material” in most online publica-
tions). Technological advances have made data sharing
and publication readily possible and we -perhaps naively
- initially expected a reasonable proportion of authors to
publish their raw data freely, the benefits of which have
been widely discussed in Trials and other journals [13].
But while sharing trial data is widely recognised as a
good idea, there are substantialc u l t u r a l ,l e g a la n de t h i -
cal challenges not yet comprehensively overcome in
sharing clinical research data.
Despite a willingness to share data, the way is not
always clear. Seeking to address some of the practical
challenges of data sharing and show leadership in trial
reporting, Trials has initiated debate [13] with the
scientific community and subsequently published gui-
dance and recommendations to increase sharing of
clinical research data. These articles have included a
code of conduct for data sharing and re-use [14] and
detailed guidelines for authors, editors and peer
reviewers on how data can be shared, and published,
while maintaining patient confidentiality [15]. These
guidelines have subsequently been adopted - and pub-
lished - in the BMJ [16]. And in 2011 Trials published
its first article with the primary purpose of making
available for alternative analyses the individual patient
data from one of the largest trials in acute stroke ever
conducted, the International Stroke Trial (IST-1) [17].
This article follows the guidance developed by Trials
and serves as an exemplar for other trialists interested
in publishing their data.
Awareness of the need for transparency in all aspects
of the research process seems to be increasing. Last year
the US Department of Health and Human Services
announced its Open Government strategy [18] and in
January 2011 a consortium of 17 major funders of pub-
lic health research committed to working towards
increased data availability [19]. And this summer’sU K
government peer review enquiry called for access to raw
data [20]. These are just a few examples and Trials,i n
partnership with our publisher, will remain committed
to enhancing data sharing and publication.
A reflection of previous trials - lessons learned
“Trials will ... present commentaries on, and critiques of,
trial reports published in other journals.” [1]
Much can be learned from non-completed trials.
TEAM (Trial on Endovascular Aneurysm Management)
was initiated in September 2006 but stopped in June
2009 after failing to reach its expected sample size [21].
Just 80 of a planned 2000 patients had been recruited.
Raymond et al.’s account of the multi-factorial reasons -
methodological, financial, cultural, ethical, bureaucratic -
for the failure of the TEAM trial demonstrates the value
afforded by openness regarding failures as well as suc-
cesses, as designers of subsequent similar trials will be
better informed. Indeed, this is one of numerous exam-
ples of Trials enabling the publication of articles that
otherwise would probably not have existed, such as our
ongoing collection on ethics issues in cluster trials [22].
Expanded versions of previously published articles
“Trials will consider for publication detailed, extended
versions of reports of RCTs that have already been pub-
lished in a conventional, short form” [1]
Recognising the deficiencies of abbreviated article for-
mats, we have encouraged trialists to submit substan-
tially extended versions of articles previously published
elsewhere. While expanded reports of trial results as yet
remain elusive, we have published several protocols
which have previously been published in summary form
-i nThe Lancet [23] and Cerebrovascular Disorders [24].
Publication of extended reports has been supported by
progressive editorial guideline development at BioMed
Central regarding duplicate and overlapping publications
[25].
Challenges still ahead
W i t h i nt h el a s tf i v ey e a r sp u b l i s h e de v i d e n c ea b o u tt h e
impact of the CONSORT statement has supported an,
albeit slow and small, improvement in the reporting of
trials [26]. But many deficiencies remain - along with
further challenges to overcome for Trials. But evidence
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trial results, and common discrepancies between regis-
tration details and both protocols and publications have
been identified [8,27,28].
Negative results
Trials encourages and facilitates the publication of all
scientifically sound trials - regardless of outcome. In
2009 Salarifar et al. reported that oral n-acetylcysteine
showed no benefit, compared to an aggressive hydration
protocol, in patients with diabetes mellitus and chronic
kidney disease [29]. This is, however, one of a relatively
small number of examples of so-called negative trials
published in the last five years. The published literature
over-emphasizes the positive; the reasons and motiva-
tions for reporting bias are many (for a review see [30]).
The pharmaceutical industry is often singled out for
suppression of results unfavourable to marketed pro-
ducts, although there are a number of contributing fac-
tors including, albeit inadvertently, journal editors and
peer reviewers [31]. We reiterate our previous calls to
make available the results of all trials, to reduce bias in
the medical evidence. Trials will consider manuscripts
previously rejected by other journals, on grounds of
‘interest level’ or space restrictions, and encourages
authors to provide any previous peer reviews to expedite
consideration by Trials. This approach saves authors’
and peer reviewers’ limited but essential time and, by
making peer review more efficient, this may help reduce
its hidden costs - conservatively estimated at £1.9bn
globally [32].
Innovation in trial reporting
Threaded publications
While Trials now regularly publishes the results of
trials, primary trial reports are predominantly published
elsewhere, and for major trials at least this is unlikely to
change. To better achieve our stated aims of facilitating
“the publication of a series of linked publications from a
single trial, beginning with the study protocol“[1] BioMed
Central has launched a ‘threaded publications’ initiative,
with Trials as key partner journal [33]. This concept of
threaded publications - clearly linking together on the
web all publications regarding a specific clinical study
regardless of where they are published - was floated in
The Lancet by Chalmers and Altman in 1999 [10]. In
2011 this has begun to be put into practice, with finan-
cial incentives - discounts on publication charges - for
authors to publish all protocols and results; innovative
article types and journals, such as Trials, to accommo-
date all trial-related publications; and technological
enhancements to the literature. Articles published in
Trials which include a trial identifier in the abstract are
now hyperlinked to the corresponding trial registration
record [34]. But the concept of threaded publications is
fundamentally important and so must go beyond a sin-
g l ej o u r n a l ,o ri n d e e das i n g l ep u b l i s h e r ,a n dt h e
required innovations to make complete trial information
more readily available must go further. The Editors of
Trials are working with BioMed Central and CrossRef,
the organisation founded by publishers which assigns
digital object identifiers to scholarly articles to help
ensure their permanence online, to develop a mechan-
ism to implement threaded publications across multiple
journals and publishers [35].
Update articles
Important changes to study protocols can be made in
t h ec o u r s eo fat r i a l ,w h i c hc u r r e n t l yd on o th a v eas u i -
table publication format. Moreover, the conclusions or
r e s u l t so fs o m es t u d i e sc a nc h a n g ea f t e rt h ee m e r g e n c e
of new data. Research updates have been proposed and
published elsewhere [36], but we are developing a speci-
fic format for publishing updates which gives each
research or protocol update a formal, separate, citable
publication.
Towards more structured reporting
Radical changes to how primary trial results are
reported and presented in journals may yet be needed.
In our editorial in 2006 we expressed the hope that we
could use “the opportunities of electronic publishing to
improve the reporting of randomised trials” [1]. This
goal remains unfulfilled, but we aim to move forward in
the next few years. There is increasing recognition that
conventional journal articles often fail to provide useable
information for readers [37]. One way to improve things
is to impose more structure. A proposal along these
lines has been made for prognosis research [38] and we
hope to explore related initiatives for reports of rando-
mised trials.
Acknowledging our contributors
Our Editorial Board has changed substantially over the
last five years, in particular by the appointment of a
growing number of Associate Editors. Indeed, the con-
tinued growth and development of the journal would
not have been possible without the expertise and sup-
port of our Editorial Board and peer reviewers, to whom
we are very grateful.
An evolving journal
The scope and policies of Trials have continued to
evolve. For example we only consider study protocols
for ongoing trials - which we now define as trials that
are still actively recruiting patients. And with the immi-
nent launch of our sister journal, Systematic Reviews
(http://www.systematicreviewsjournal.com), we now
encourage all systematic review products -including sys-
tematic reviews of randomised trials - to be submitted
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working with the Editors of Systematic Reviews and past
and future contributors to Trials over the next five
years to further address the challenges of enhancing the
reporting of healthcare research.
Appendix 1
Reviewers of study protocols for Trials are asked to con-
sider the following points:
1. Will the study design adequately test the
hypothesis?
2. Are sufficient details provided to allow replication
of the work or comparison with related analyses: if
not, what is missing?
3. Is the planned statistical analysis appropriate?
4. Is the writing acceptable?
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